CA-EYENUK-INC
12.9.2019 09:07:08 CEST | Business Wire | Press release
Eyenuk Inc. , a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that the EyeArt® AI Eye Screening System was deployed successfully for Italy’s first national prevention and diagnosis campaign for retinal and diabetic maculopathy. A total of 2,200 patients were screened at 30 centers across Italy, with more than half chosen for EyeArt AI Eye Screening. The Month of Prevention of Diabetic Retinopathy and Maculopathy was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society in collaboration with the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk.
In Italy, an estimated 3.2 million patients have diabetes. As many as 25% are estimated to be affected by diabetic retinopathy (DR),1 the main cause of vision impairment and blindness among working-age adults. DR occurs when high blood sugar levels lead to damage of the blood vessels in the light-sensitive tissue at the back of the eye, called the retina. Annual eye screening is recommended for people with diabetes since DR can progress silently without any perceptible symptoms or vision deterioration.
The EyeArt AI System uses artificial intelligence algorithms to autonomously analyze images of the eye taken with a retinal camera. Of the patients who underwent EyeArt AI Eye Screening, 214 patients were identified as having referable DR never diagnosed before; all were referred to eye care specialists to save their vision. The EyeArt AI System is the most extensively validated AI technology for autonomous detection of DR to date, tested in real-world settings on more than a half-million patient visits with more than 2 million images collected globally. In a prospective, pivotal clinical trial on more than 900 patients, the EyeArt System was shown to have 95.5% sensitivity and 86% specificity for detecting referable DR.
"Using the EyeArt AI System for our screening campaign was an extraordinary success. Nearly 17% of the patients screened had never received a complete diabetic eye exam, and another 8% hadn’t been screened in more than four years," says Dr. Lucio Buratto, scientific director of CAMO. “With the EyeArt AI System, we were able to examine thousands of patients in a fraction of the time that it would have otherwise taken. We can conclude that a prompt diagnosis and proper treatment could reduce 50-70% of the cases that show a severe visual impairment due to diabetes and DR. What’s more, early detection means the cost of health and social care will be significantly lower. We look forward to using the EyeArt AI System in future campaigns and in our clinics.”
The EyeArt AI System allows diabetes care providers to quickly and accurately identify patients with referable DR, without needing eye care expertise on-site, so at-risk patients can be immediately referred to an ophthalmologist for further evaluation and vision-saving treatment. The EyeArt AI System removes the biggest obstacles to annual DR screening and diagnosis: timely access to screening and patient compliance.
“We are proud to be part of the first national screening campaign for diabetic retinopathy and maculopathy in Italy,” says Kaushal Solanki, CEO of Eyenuk. “Giving eye care providers the power to quickly screen thousands of people is gratifying, and we look forward to participating in similar initiatives worldwide.”
Eyenuk will showcase its EyeArt AI Eye Screening System at the European Association for the Study of Diabetes (EASD) annual meeting (Booth #D.02) Sept. 16-20, 2019, in Barcelona, Spain.
VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy from Dr. Buratto .
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System provides fully automated DR screening, including retinal imaging, DR grading on international standards and reporting on-site, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR screening results are available in a PDF report in less than 60 seconds.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of DR. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website , Twitter , Facebook , and LinkedIn .
The EyeArt System has CE marking and has been cleared for sales as a Class IIa medical device by the European Union and as a Class 2 medical device by Health Canada. In the U.S., the EyeArt System is limited to investigational use only.
EyeArt® is a registered trademark of Eyenuk Inc.
_________________________________
1
https://www.istat.it/en/archivio/202712
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005294/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom